|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another use could be adding mass RTS,S/AS01 vaccination to the integrated malaria elimination strategy in the Greater Mekong Subregion (GMS), where multidrug-resistant <i>P.falciparum</i> strains have emerged and spread.
|
31306084 |
2020 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The AS01 adjuvant is used in the malaria vaccine RTS,S/AS01 and in the licensed herpes-zoster vaccine (Shingrix) where the vaccine has proven its ability to generate protective responses with both robust humoral and T-cell responses.
|
31572370 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African children and infants.
|
31092823 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of the AS, the Herpes Zoster vaccine (HZ/su) (Shingrix™) which received a license in 2017 from the FDA and a marketing authorization in the EU in 2018 and the RTS,S/AS01 vaccine (Mosquirix™) against malaria, which was approved by the EMA in 2015 for further implementation in Sub-Saharan countries for routine use.
|
31182297 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The licensing of RTS, S/AS01 is a step forward in providing some protection, but a malaria vaccine that protects across multiple transmission seasons is still needed.
|
30601095 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria.
|
31012786 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the leading malaria vaccine, RTS,S/AS01, with modest efficacy is being evaluated in a pilot feasibility trial, development of a malaria transmission-blocking vaccine (TBV) could make a major contribution toward malaria elimination.
|
31566026 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated IgM and IgG responses to 38 P. falciparum proteins putatively involved in naturally acquired immunity to malaria in 195 young children participating in a case-control study nested within the African phase 3 clinical trial of RTS,S/AS01E (MAL055 NCT00866619) in two sites of different transmission intensity (Kintampo high and Manhiça moderate/low).
|
31409398 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the development of more efficacious vaccines by improving the formulation of RTS,S for increased efficacy or to interrupt malaria transmission are urgently needed.
|
31504038 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum samples were selected from children in a phase IIb trial of RTS,S/AS02<sub>A</sub> conducted at two study sites of high and low malaria transmission intensity in Manhiça, Mozambique.
|
30798787 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed plasma and serum samples at baseline and 1 month after primary vaccination with RTS,S or comparator in African children and infants participating in a phase 3 trial in two sites of different malaria transmission intensity: Kintampo in Ghana and Manhiça in Mozambique.
|
30930896 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical profile of severe paediatric malaria in an area targeted for routine RTS,S/AS01 malaria vaccination in Western Kenya.
|
31504308 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTS,S/AS01 vaccine is the first malaria vaccine being licensed for use against P. falciparum malaria.
|
28560654 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels pre-vaccination, were associated with malaria risk over 1-year follow-up.
|
30376866 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The candidate malaria vaccine RTS,S has demonstrated 45.7% efficacy over 18 months against all clinical disease in a phase-III field study of African children.
|
28934066 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTS,S/AS01, the most advanced malaria vaccine to date, targets the parasite before it invades the liver and has the potential to prevent malaria disease as well as transmission by preventing blood stage infection and therefore gametocytogenesis.
|
30564231 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human mAb derived from plasmablasts of recipients of RTS,S/AS01 (RTS,S), the most advanced malaria vaccine candidate, were used in the assay development to measure Ag-specific binding responses and rate constants of association and dissociation.
|
30006374 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the analyses presented here give an indication that HLA genotype may influence RTS,S-mediated protective efficacy against malaria infection.
|
29439870 |
2018 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These studies identify an anti-sporozoite vaccine component that may improve upon the current leading malaria vaccine RTS,S.
|
28422178 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTS,S is an advanced malaria vaccine candidate and confers significant protection against <i>Plasmodium falciparum</i> infection in humans.
|
28193898 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood-stage malaria vaccines protect against disease, and are considered effective targets for the logical design of next generation vaccines to improve the RTS,S field efficacy.
|
28604122 |
2017 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With demonstration purpose, we apply the software to 30 cytokines, chemokines and growth factors measured in a multiplex bead-based immunoassay in a study aiming to measure correlates of risk or protection from malaria of the RTS,S malaria vaccine nested in the Phase 3 randomized controlled trial of this vaccine.
|
29136653 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
|
27890400 |
2017 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This strategy can complement the malaria control portfolio even if the antimalarial component is only partially effective and has led to the development of the only candidate vaccine to date, namely RTS,S-AS01.
|
28500775 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent experience with Seasonal Malaria Chemoprevention and with the RTS,S/AS01 malaria vaccine provides examples of interventions which need to be deployed on a restricted rather than a national basis, taking account of differences in climate and the intensity of malaria infection between regions within a country.
|
28646958 |
2017 |